Virginia's attorney general has sued several major pharmaceutical companies, claiming inflated insulin prices harm consumers ...

The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President ...

Virginia is accusing some of the largest names in the prescription drug industry of artificially inflating the prices of insulin, a life-saving medication, over the course of several years.

Charlotte officials claimed in the lawsuit that insulin, which costs about $2 to produce, can be sold by manufacturers for as much as $700.

The Trump administration on Friday announced deals with nine drugmakers aimed at lowering pharmaceutical prices, bringing its total number of drug-pricing agreements to 14.

The commonwealth claims that pharmacy benefit managers and drug manufacturers are in cahoots to inflate insulin prices for ...

President Trump announced landmark drug pricing agreements with nine pharmaceutical companies and the launch of TrumpRx.gov, aiming to lower US medicine prices and align them with Europe while warning ...

Attorney General Jason Miyares today filed a lawsuit against the nation’s largest pharmacy benefit managers and insulin manufacturers in the Circuit Court for ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss market. These healthcare companies have tremendous long-term growth ...